MVP
$43MCF+
Medical Developments International
Pain management
Manufacturer of Penthrox (inhaled methoxyflurane) for acute pain — approved in 20+ countries
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$16.9M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$43M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
113M
Pipeline Assets
3
Latest Insight(1)
16 Apr 2026substantial_holderChange in substantial holding
Changed·Regal Partners Funds Management Pty Limited and its associates·9.14%
3M Price
MVP.ASX$0.385-25.2% 3M
Low $0.370High $0.515
Pipeline Assets (3)
Penthrox USacute trauma pain
Phase 3Penthroxacute trauma pain (adult)
ApprovedPenthrox Paediatricacute trauma pain (paediatric)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Substantial Holders (5%+ threshold)
1 noticearrow_drop_downRegal Partners Funds Management Pty Limited and its associates
9.14%2026-04-14
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
12 competitor trialsPhase 2+ · Non-ASX
Acute Trauma Pain11 active trials
7 Ph42 Ph32 Ph2
Acute Trauma Pain (Paediatric)1 active trial
1 Ph3
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
2 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Injury2026-04· Penthrox
Scand J Trauma Resusc Emerg Med2026-03· Penthrox
Catalysts (1)
SpeculativeremoveMed1 June 2029
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| PHASE3 data readout — Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute open_in_new Primary completion expected for NCT07445737. Indication: {"STEMI - ST Elevation Myocardial Infarction"} | data readout | Speculative | removeMed |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph3Not Yet Recruiting
MethoxyfluraneMorphine
Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction
STEMI - ST Elevation Myocardial Infarction
RandomizedOpen Label18 Years+
Primary endpoint Demonstrate that methoxyflurane self-administered by the patient is at least as efficient in achieving pain relief that morphine
Announcements(7)
description
Half YearPSauto_awesome
FY26 Half Year Report (including Appendix 4D)18 Feb 2026
expand_more1367KB